CoChat
Sign Up
Cited by 40

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-β in vitro

Bergamaschini, Luigi, Donarini, Cesare, Rossi, Emanuela, De Luigi, Ada, Vergani, Carlo, Grazia De Simoni, Maria·2002·Neurobiology of Aging
DOI 10.1016/s0197-4580(02)00003-9
Open this paper in CoChat — free account

Abstract

Amyloid-beta protein (Abeta) is implicated in the pathogenesis of Alzheimer's disease because of its neurotoxicity and the ability to trigger local inflammation. Compounds that interact with the amino acids of the N-terminal region or interfere with aggregation can reduce the Abeta biologic activity. We evaluated the effect of heparin on Abeta (1-42) neurotoxicity and on its ability to activate complement and contact system. On differentiated PC12 cells, a reliable model of neuronal cells, heparin at the doses of 10 and 20 microg/ml significantly counteracted Abeta cytotoxicity as assessed by measuring MTT conversion. We then explored the effect of heparin on Abeta (1-42)-induced complement and contact system activation. Abeta (1-42) was incubated with heparin in presence of normal plasma as the source of complement and contact system factors. Heparin reduced, in a dose-dependent manner, complement and contact system activation, assessed by measuring the degree of C4 and high molecular weight kininogen cleavage. The present data show that heparin can attenuate neurotoxic and pro-inflammatory activity of Abeta and suggest that this drug could represent a new strategy to reduce the progressive neurodegeneration in AD.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0197-4580(02)00003-9

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 45

  1. Aisen, 1994, Inflammatory mechanisms in Alzheimer’s disease, Am J Psychiatry, 151, 1105, 10.1176/ajp.151.8.1105 · DOI
  2. Bergamaschini, 1999, Alzheimer’s beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner, Clin Exp Immunol, 115, 526, 10.1046/j.1365-2249.1999.00835.x · DOI
  3. Bergamaschini, 2001, The region 1–11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system, Neurobiol Aging, 22, 63, 10.1016/S0197-4580(00)00174-3 · DOI
  4. Bergamaschini, 1998, Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease, Alzheimer Dis Assc Dis, 12, 102, 10.1097/00002093-199806000-00008 · DOI
  5. Berrettini, 1986, Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies, Blood, 68, 455, 10.1182/blood.V68.2.455.455 · DOI
  6. Bertram, 2000, Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q, Science, 290, 2302, 10.1126/science.290.5500.2302 · DOI
  7. Bradt, 1998, Complement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide, J Exp Med, 188, 431, 10.1084/jem.188.3.431 · DOI
  8. Caldwell, 1999, Heparin binding and augmentation of C1 inhibitor activity, Arch Biochem Biophys, 361, 215, 10.1006/abbi.1998.0996 · DOI
  9. Castillo, 1999, The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation, J Neurochem, 72, 1681, 10.1046/j.1471-4159.1999.721681.x · DOI
  10. Castillo, 1997, Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer’s disease, accelerates A beta fibril formation, and maintains A beta fibril stability, J Neurochem, 69, 2452, 10.1046/j.1471-4159.1997.69062452.x · DOI · Paper page
  11. Caughman, 1982, A postulated mechanism for heparin’s potentiation of C1 inhibitor function, Mol Immunol, 19, 287, 10.1016/0161-5890(82)90342-X · DOI
  12. Chen, 1996, Neuroglial-mediated immunoinflammatory responses in Alzheimer’s disease, Neurobiol Aging, 17, 781, 10.1016/0197-4580(96)00103-0 · DOI
  13. Colman, 1997, Contact system, Blood, 90, 3819, 10.1182/blood.V90.10.3819 · DOI
  14. Cotman, 1996, Beta-Amyloid converts an acute phase injury response to chronic injury responses, Neurobiol Aging, 17, 723, 10.1016/0197-4580(96)00117-0 · DOI
  15. Emmerling, 2000, The role of complement in Alzheimer’s disease pathology, Biochimica et Biophysica Acta, 1502, 158, 10.1016/S0925-4439(00)00042-9 · DOI
  16. Ertekin-Taner, 2000, Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees, Science, 290, 2303, 10.1126/science.290.5500.2303 · DOI
  17. Forloni, 2000, Alpha-synuclein and Parkinson’s disease, Ann Neurol, 47, 632, 10.1002/1531-8249(200005)47:5<632::AID-ANA11>3.3.CO;2-E · DOI
  18. Frenkel, 2000, Immunization against Alzheimer’s beta -amyloid plaques via EFRH phage administration, Proc Natl Acad Sci USA, 97, 11455, 10.1073/pnas.97.21.11455 · DOI
  19. Gallimore, 1992, Contact activation, heparins and cardiopulmonary bypass, Thromb Haemost, 68, 91, 10.1055/s-0038-1656327 · DOI
  20. Games, 2000, Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1–42, Ann NY Acad Sci, 920, 274, 10.1111/j.1749-6632.2000.tb06936.x · DOI
  21. Harkany, 2000, Mechanisms of beta-amyloid neurotoxicity, Rev Neurosci, 11, 329, 10.1515/REVNEURO.2000.11.4.329 · DOI
  22. Janus, 2000, A beta peptide immunization reduces behavioural impairment, and plaques in a model of Alzheimer’s disease, Nature, 408, 979, 10.1038/35050110 · DOI · Paper page
  23. Joseph, 1999, Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer’s disease, Immunopharmacology, 43, 203, 10.1016/S0162-3109(99)00136-8 · DOI
  24. Kay, 1987, CSF, and serum concentrations of albumin, and IgG in Alzheimer’s disease, Neurobiol Aging, 8, 21, 10.1016/0197-4580(87)90053-4 · DOI
  25. Kuo, 2000, Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism, Am J Pathol, 156, 797, 10.1016/S0002-9440(10)64947-4 · DOI · Paper page
  26. Lammle, 1988, Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor XI, Thromb Haemost, 59, 151, 10.1055/s-0038-1642745 · DOI
  27. Leveugle, 1994, Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide, Neuroreport, 5, 1389
  28. Levy, 1981, Immunoglobulin-sulfated polysaccharide interactions. Binding of agaropectin and heparin by human IgG proteins, J Exp Med, 153, 883, 10.1084/jem.153.4.883 · DOI
  29. Mackic, 1998, Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer’s amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy, J Neurochem, 70, 210, 10.1046/j.1471-4159.1998.70010210.x · DOI · Paper page
  30. Manthorpe, 1986, An automated colorimetric microassay for neuronotrophic factors, Brain Res, 390, 191, 10.1016/0165-3806(86)90208-7 · DOI
  31. McGeer, 1999, Brain inflammation in Alzheimer disease and the therapeutic implications, Curr Pharm Des, 5, 821, 10.2174/1381612805666230111212056 · DOI
  32. Myers, 2000, Susceptibility locus for Alzheimer’s disease on chromosome 10, Science, 290, 2304, 10.1126/science.290.5500.2304 · DOI
  33. Pixley, 1991, Effect of heparin on the activation of factor XII and the contact system in plasma, Thromb Haemost, 66, 540, 10.1055/s-0038-1646456 · DOI
  34. Pollack, 1995, Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells, Neurosci Lett, 184, 113, 10.1016/0304-3940(94)11182-I · DOI
  35. Sahu, 2000, Complement inhibitors, Immunopharmacology, 49, 133, 10.1016/S0162-3109(00)80299-4 · DOI
  36. Schlageter, 1987, Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography, J Cereb Blood Flow Metab, 7, 1, 10.1038/jcbfm.1987.1 · DOI
  37. Shibayama, 1999, Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein, Clin Immunol, 90, 89, 10.1006/clim.1998.4621 · DOI
  38. Strazielle, 2000, In vitro evidence that beta-amyloid peptide 1–40 diffuses across the blood-brain barrier and affects its permeability, J Neuropathol Exp Neurol, 59, 29, 10.1093/jnen/59.1.29 · DOI
  39. Tyrrell, 1999, Heparin in inflammation, Adv Pharmacol, 46, 151, 10.1016/S1054-3589(08)60471-8 · DOI
  40. Veerhuis, 1998, Complement C1-inhibitor expression in Alzheimer’s disease, Acta Neuropathol (Berl), 96, 287, 10.1007/s004010050896 · DOI
  41. Velazquez, 1997, Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation, Nat Med, 3, 77, 10.1038/nm0197-77 · DOI
  42. Walport, 2001, Complement. First of two parts, N Engl J Med, 344, 1058, 10.1056/NEJM200104053441406 · DOI
  43. Walport, 2001, Complement. Second of two parts, N Engl J Med, 344, 1140, 10.1056/NEJM200104123441506 · DOI
  44. Watson, 1997, Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red, J Biol Chem, 272, 31617, 10.1074/jbc.272.50.31617 · DOI
  45. Yasuhara, 1994, Hageman factor and its binding sites are present in senile plaques of Alzheimer’s disease, Brain Research, 654, 234, 10.1016/0006-8993(94)90484-7 · DOI

Cited by

Sorted by citations

Metadata

Authors
Bergamaschini, L., Donarini, C., Rossi, E., De Luigi, A., Vergani, C., & Grazia De Simoni, M.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2002-07
Volume
23
Issue
4
Pages
531-536
ISSN
0197-4580
DOI
10.1016/s0197-4580(02)00003-9
Cited by
40
References
5
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review